Bunazosin Hydrochloride | CAS#52712-76-2 | Alpha(1)-Adrenoceptor Antagonist

MedKoo Cat#: 329209 | Name: Bunazosin Hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bunazosin Hydrochloride, also known as Andante and E-643, is an alpha(1)-adrenoceptor antagonist used as a systemic antihypertensive and an ocular hypotensive drug.

Chemical Structure

Bunazosin Hydrochloride

CAS#52712-76-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 329209

Name: Bunazosin Hydrochloride

CAS#: 52712-76-2 (HCl)

Chemical Formula: C19H28ClN5O3

Exact Mass: 409.1881

Molecular Weight: 409.92

Elemental Analysis: C, 55.67; H, 6.89; Cl, 8.65; N, 17.09; O, 11.71

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,250.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

80755-51-7(free base) 52712-76-2 (HCl)

Synonym

Bunazosin Hydrochloride; E-643; E-1015; E 643; E 1015; E643; E1015; Andante

IUPAC/Chemical Name

1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl)butan-1-one hydrochloride

InChi Key

NBGBEUITCPENLJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H27N5O3.ClH/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19;/h11-12H,4-10H2,1-3H3,(H2,20,21,22);1H

SMILES Code

CCCC(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CCC1)=O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#: T8R09C28

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

TBD

In vitro activity:

TBD

In vivo activity:

TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 409.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Goto W, Ichikawa M, Tanaka E, Hara H, Araie M. Bunazosin hydrochloride reduces glutamate-induced neurotoxicity in rat primary retinal cultures. Brain Res. 2004 Apr 2;1003(1-2):130-7. doi: 10.1016/j.brainres.2003.12.030. PMID: 15019572. 2: Kobayashi H, Kobayashi K, Okinami S. Efficacy of bunazosin hydrochloride 0.01% as adjunctive therapy of latanoprost or timolol. J Glaucoma. 2004 Feb;13(1):73-80. doi: 10.1097/00061198-200402000-00014. PMID: 14704548. 3: Oshika T, Araie M, Sugiyama T, Nakajima M, Azuma I. Effect of bunazosin hydrochloride on intraocular pressure and aqueous humor dynamics in normotensive human eyes. Arch Ophthalmol. 1991 Nov;109(11):1569-74. doi: 10.1001/archopht.1991.01080110105046. PMID: 1684492. 4: Hara H, Ichikawa M, Oku H, Shimazawa M, Araie M. Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56. doi: 10.1111/j.1527-3466.2005.tb00156.x. PMID: 15867947. 5: Hu WY, Fukuda N, Soma M, Izumi Y, Kanmatsuse K. Bunazosin hydrochloride inhibits exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats by suppressing the response to growth factors. J Cardiovasc Pharmacol. 1998 Dec;32(6):975-82. doi: 10.1097/00005344-199812000-00015. PMID: 9869504. 6: Kumamoto Y, Tsukamoto T, Yachiku S, Kaneko S, Koyanagi T, Togashi M, Maru A, Tsuchida S, Nishizawa O, Orikasa S, et al. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy]. Hinyokika Kiyo. 1990 Oct;36(10):1213-32. Japanese. PMID: 1702262. 7: Akaishi T, Takagi Y, Matsugi T, Ishida N, Hara H, Kashiwagi K. Effects of bunazosin hydrochloride on ciliary muscle constriction and matrix metalloproteinase activities. J Glaucoma. 2004 Aug;13(4):312-8. doi: 10.1097/00061198-200408000-00009. PMID: 15226660. 8: Zhan GL, Toris CB, Camras CB, Wang YL, Yablonski ME. Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow. J Ocul Pharmacol Ther. 1998 Jun;14(3):217-28. doi: 10.1089/jop.1998.14.217. PMID: 9671429. 9: Weidinger G. Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. Arzneimittelforschung. 1995 Nov;45(11):1166-71. PMID: 8929232. 10: Goto W, Oku H, Okuno T, Sugiyama T, Ikeda T. Amelioration by topical bunazosin hydrochloride of the impairment in ocular blood flow caused by nitric oxide synthase inhibition in rabbits. J Ocul Pharmacol Ther. 2003 Feb;19(1):63-73. doi: 10.1089/108076803762718123. PMID: 12648305. 11: Ogura T, Katayama E, Mitsui T, Takatori K, Ota Z, Mizukawa K, Ogawa N. Properties of [3H]bunazosin binding in rat kidney. Clin Ther. 1988;10(5):559-67. PMID: 2908804. 12: Yamada S, Suzuki M, Matsuoka Y, Kato Y, Kimura R, Maruyama M, Kawabe K. [3H]bunazosin, a novel selective radioligand of alpha 1 adrenoceptors in human prostates. J Urol. 1991 Sep;146(3):877-80. doi: 10.1016/s0022-5347(17)37952-1. PMID: 1714973. 13: Mochizuki Y, Oishi M, Takasu T. Effects of bunazosin hydrochloride sustained-release formulation on cerebral circulation. Int Angiol. 2000 Mar;19(1):35-8. PMID: 10853683. 14: Kato A, Ishibashi Y, Miyake Y. Effect of egg yolk lecithin on transdermal delivery of bunazosin hydrochloride. J Pharm Pharmacol. 1987 May;39(5):399-400. doi: 10.1111/j.2042-7158.1987.tb03407.x. PMID: 2886592. 15: Kumamoto Y, Tsukamoto T, Takagi Y, Furuya S, Yokoyama E, Takatsuka K, Tamiya T, Miyamoto S, Aoyama T, Honma A. [Clinical efficacy of oxendolene (antiandrogen) and bunazosin hydrochloride (alpha-adrenergic blocker) in the treatment of prostatism--comparative study of oxendolone, bunazocin hydrochloride and their combination]. Hinyokika Kiyo. 1987 Nov;33(11):1921-41. Japanese. PMID: 2451412. 16: Yoshikawa K, Katsushima H, Kimura T, Yamagishi K, Yamabayashi S. Addition of or switch to topical bunazosin hydrochloride in elderly patients with normal- tension glaucoma: A one-year follow-up study. Jpn J Ophthalmol. 2006 Sep- Oct;50(5):443-448. doi: 10.1007/s10384-006-0351-z. PMID: 17013697. 17: Ichikawa M, Okada Y, Asai Y, Hara H, Ishii K, Araie M. Effects of topically instilled bunazosin, an alpha1-adrenoceptor antagonist, on constrictions induced by phenylephrine and ET-1 in rabbit retinal arteries. Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4041-8. doi: 10.1167/iovs.03-1395. PMID: 15505054. 18: Okada Y, Ichikawa M, Ishii K, Hara H. Effects of topically instilled bunazosin hydrochloride and other ocular hypotensive drugs on endothelin-1-induced constriction in rabbit retinal arteries. Jpn J Ophthalmol. 2004 Sep-Oct;48(5):465-9. doi: 10.1007/s10384-004-0108-5. PMID: 15486769. 19: Kato A, Iwata S. Studies on improved corneal permeability to bunazosin. J Pharmacobiodyn. 1988 May;11(5):330-4. doi: 10.1248/bpb1978.11.330. PMID: 2902207. 20: Yasuda G, Umemura S, Ishii M. Characterization of bunazosin-sensitive alpha1-adrenoceptors in human renal medulla. J Cardiovasc Pharmacol. 1997 Aug;30(2):163-8. doi: 10.1097/00005344-199708000-00003. PMID: 9269942.